Cargando…
The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3)
BACKGROUND: Dipeptidyl peptidase-4 (DPP-4) inhibitors may have protective effects in the early stage of atherosclerosis in patients with type 2 diabetes, although similar effects in advanced atherosclerosis were not shown in recent randomized placebo-controlled studies. Therefore, we investigated th...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5634845/ https://www.ncbi.nlm.nih.gov/pubmed/29017497 http://dx.doi.org/10.1186/s12933-017-0607-6 |
_version_ | 1783270171823046656 |
---|---|
author | Kitao, Naoyuki Miyoshi, Hideaki Furumoto, Tomoo Ono, Kota Nomoto, Hiroshi Miya, Aika Yamamoto, Chiho Inoue, Atsushi Tsuchida, Kenichi Manda, Naoki Kurihara, Yoshio Aoki, Shin Nakamura, Akinobu Atsumi, Tatsuya |
author_facet | Kitao, Naoyuki Miyoshi, Hideaki Furumoto, Tomoo Ono, Kota Nomoto, Hiroshi Miya, Aika Yamamoto, Chiho Inoue, Atsushi Tsuchida, Kenichi Manda, Naoki Kurihara, Yoshio Aoki, Shin Nakamura, Akinobu Atsumi, Tatsuya |
author_sort | Kitao, Naoyuki |
collection | PubMed |
description | BACKGROUND: Dipeptidyl peptidase-4 (DPP-4) inhibitors may have protective effects in the early stage of atherosclerosis in patients with type 2 diabetes, although similar effects in advanced atherosclerosis were not shown in recent randomized placebo-controlled studies. Therefore, we investigated the efficacy of DPP-4 inhibitor on endothelial function and glycemic metabolism compared with high-dose metformin. METHODS: In this multicenter, open-labeled, prospective, randomized, parallel-group comparison study, patients with type 2 diabetes treated with low-dose metformin (500–750 mg/day) were enrolled and randomly assigned to a vildagliptin, a DPP-4 inhibitor, add-on group (Vilda) or a double dose of metformin group (high Met) for 12 weeks. Flow-mediated dilation (FMD) and serum metabolic markers were assessed before and after treatment. In addition, glycemic control and metabolic parameters were also assessed. RESULTS: Ninety-seven subjects (aged 58.7 ± 11.0 years; body mass index, 25.9 ± 4.4 kg/m(2); HbA1c, 7.3 ± 0.5%; FMD, 5.8 ± 2.6%) were enrolled. Eight subjects dropped out by the end of the study. There were no significant differences between the two groups in baseline characteristics. After 12 weeks, HbA1c was significantly improved in the Vilda group compared with the high Met group (− 0.80 ± 0.38% vs. − 0.40 ± 0.47%, respectively; p < 0.01). However, there were no significant differences in FMD (− 0.51 [− 1.08–0.06]% vs. − 0.58 [− 1.20–0.04]%). Although the apolipoprotein B/apolipoprotein A1 ratio was significantly reduced in the Vilda group compared with baseline (0.66–0.62; p < 0.01), the change did not differ significantly between the two groups (− 0.04 vs. 0.00; p = 0.27). Adiponectin levels were significantly increased in the Vilda group compared with the high Met group (0.75 μg/mL vs. 0.01 μg/mL; p < 0.01). CONCLUSIONS: Regardless of glycemic improvement, combination therapy of vildagliptin and metformin did not affect endothelial function but may exert favorable effects on adipokine levels and lipid profile in patients with type 2 diabetes without advanced atherosclerosis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12933-017-0607-6) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5634845 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-56348452017-10-19 The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3) Kitao, Naoyuki Miyoshi, Hideaki Furumoto, Tomoo Ono, Kota Nomoto, Hiroshi Miya, Aika Yamamoto, Chiho Inoue, Atsushi Tsuchida, Kenichi Manda, Naoki Kurihara, Yoshio Aoki, Shin Nakamura, Akinobu Atsumi, Tatsuya Cardiovasc Diabetol Original Investigation BACKGROUND: Dipeptidyl peptidase-4 (DPP-4) inhibitors may have protective effects in the early stage of atherosclerosis in patients with type 2 diabetes, although similar effects in advanced atherosclerosis were not shown in recent randomized placebo-controlled studies. Therefore, we investigated the efficacy of DPP-4 inhibitor on endothelial function and glycemic metabolism compared with high-dose metformin. METHODS: In this multicenter, open-labeled, prospective, randomized, parallel-group comparison study, patients with type 2 diabetes treated with low-dose metformin (500–750 mg/day) were enrolled and randomly assigned to a vildagliptin, a DPP-4 inhibitor, add-on group (Vilda) or a double dose of metformin group (high Met) for 12 weeks. Flow-mediated dilation (FMD) and serum metabolic markers were assessed before and after treatment. In addition, glycemic control and metabolic parameters were also assessed. RESULTS: Ninety-seven subjects (aged 58.7 ± 11.0 years; body mass index, 25.9 ± 4.4 kg/m(2); HbA1c, 7.3 ± 0.5%; FMD, 5.8 ± 2.6%) were enrolled. Eight subjects dropped out by the end of the study. There were no significant differences between the two groups in baseline characteristics. After 12 weeks, HbA1c was significantly improved in the Vilda group compared with the high Met group (− 0.80 ± 0.38% vs. − 0.40 ± 0.47%, respectively; p < 0.01). However, there were no significant differences in FMD (− 0.51 [− 1.08–0.06]% vs. − 0.58 [− 1.20–0.04]%). Although the apolipoprotein B/apolipoprotein A1 ratio was significantly reduced in the Vilda group compared with baseline (0.66–0.62; p < 0.01), the change did not differ significantly between the two groups (− 0.04 vs. 0.00; p = 0.27). Adiponectin levels were significantly increased in the Vilda group compared with the high Met group (0.75 μg/mL vs. 0.01 μg/mL; p < 0.01). CONCLUSIONS: Regardless of glycemic improvement, combination therapy of vildagliptin and metformin did not affect endothelial function but may exert favorable effects on adipokine levels and lipid profile in patients with type 2 diabetes without advanced atherosclerosis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12933-017-0607-6) contains supplementary material, which is available to authorized users. BioMed Central 2017-10-10 /pmc/articles/PMC5634845/ /pubmed/29017497 http://dx.doi.org/10.1186/s12933-017-0607-6 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Original Investigation Kitao, Naoyuki Miyoshi, Hideaki Furumoto, Tomoo Ono, Kota Nomoto, Hiroshi Miya, Aika Yamamoto, Chiho Inoue, Atsushi Tsuchida, Kenichi Manda, Naoki Kurihara, Yoshio Aoki, Shin Nakamura, Akinobu Atsumi, Tatsuya The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3) |
title | The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3) |
title_full | The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3) |
title_fullStr | The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3) |
title_full_unstemmed | The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3) |
title_short | The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3) |
title_sort | effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (sapporo athero-incretin study 3) |
topic | Original Investigation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5634845/ https://www.ncbi.nlm.nih.gov/pubmed/29017497 http://dx.doi.org/10.1186/s12933-017-0607-6 |
work_keys_str_mv | AT kitaonaoyuki theeffectsofvildagliptincomparedwithmetforminonvascularendothelialfunctionandmetabolicparametersarandomizedcontrolledtrialsapporoatheroincretinstudy3 AT miyoshihideaki theeffectsofvildagliptincomparedwithmetforminonvascularendothelialfunctionandmetabolicparametersarandomizedcontrolledtrialsapporoatheroincretinstudy3 AT furumototomoo theeffectsofvildagliptincomparedwithmetforminonvascularendothelialfunctionandmetabolicparametersarandomizedcontrolledtrialsapporoatheroincretinstudy3 AT onokota theeffectsofvildagliptincomparedwithmetforminonvascularendothelialfunctionandmetabolicparametersarandomizedcontrolledtrialsapporoatheroincretinstudy3 AT nomotohiroshi theeffectsofvildagliptincomparedwithmetforminonvascularendothelialfunctionandmetabolicparametersarandomizedcontrolledtrialsapporoatheroincretinstudy3 AT miyaaika theeffectsofvildagliptincomparedwithmetforminonvascularendothelialfunctionandmetabolicparametersarandomizedcontrolledtrialsapporoatheroincretinstudy3 AT yamamotochiho theeffectsofvildagliptincomparedwithmetforminonvascularendothelialfunctionandmetabolicparametersarandomizedcontrolledtrialsapporoatheroincretinstudy3 AT inoueatsushi theeffectsofvildagliptincomparedwithmetforminonvascularendothelialfunctionandmetabolicparametersarandomizedcontrolledtrialsapporoatheroincretinstudy3 AT tsuchidakenichi theeffectsofvildagliptincomparedwithmetforminonvascularendothelialfunctionandmetabolicparametersarandomizedcontrolledtrialsapporoatheroincretinstudy3 AT mandanaoki theeffectsofvildagliptincomparedwithmetforminonvascularendothelialfunctionandmetabolicparametersarandomizedcontrolledtrialsapporoatheroincretinstudy3 AT kuriharayoshio theeffectsofvildagliptincomparedwithmetforminonvascularendothelialfunctionandmetabolicparametersarandomizedcontrolledtrialsapporoatheroincretinstudy3 AT aokishin theeffectsofvildagliptincomparedwithmetforminonvascularendothelialfunctionandmetabolicparametersarandomizedcontrolledtrialsapporoatheroincretinstudy3 AT nakamuraakinobu theeffectsofvildagliptincomparedwithmetforminonvascularendothelialfunctionandmetabolicparametersarandomizedcontrolledtrialsapporoatheroincretinstudy3 AT atsumitatsuya theeffectsofvildagliptincomparedwithmetforminonvascularendothelialfunctionandmetabolicparametersarandomizedcontrolledtrialsapporoatheroincretinstudy3 AT theeffectsofvildagliptincomparedwithmetforminonvascularendothelialfunctionandmetabolicparametersarandomizedcontrolledtrialsapporoatheroincretinstudy3 AT kitaonaoyuki effectsofvildagliptincomparedwithmetforminonvascularendothelialfunctionandmetabolicparametersarandomizedcontrolledtrialsapporoatheroincretinstudy3 AT miyoshihideaki effectsofvildagliptincomparedwithmetforminonvascularendothelialfunctionandmetabolicparametersarandomizedcontrolledtrialsapporoatheroincretinstudy3 AT furumototomoo effectsofvildagliptincomparedwithmetforminonvascularendothelialfunctionandmetabolicparametersarandomizedcontrolledtrialsapporoatheroincretinstudy3 AT onokota effectsofvildagliptincomparedwithmetforminonvascularendothelialfunctionandmetabolicparametersarandomizedcontrolledtrialsapporoatheroincretinstudy3 AT nomotohiroshi effectsofvildagliptincomparedwithmetforminonvascularendothelialfunctionandmetabolicparametersarandomizedcontrolledtrialsapporoatheroincretinstudy3 AT miyaaika effectsofvildagliptincomparedwithmetforminonvascularendothelialfunctionandmetabolicparametersarandomizedcontrolledtrialsapporoatheroincretinstudy3 AT yamamotochiho effectsofvildagliptincomparedwithmetforminonvascularendothelialfunctionandmetabolicparametersarandomizedcontrolledtrialsapporoatheroincretinstudy3 AT inoueatsushi effectsofvildagliptincomparedwithmetforminonvascularendothelialfunctionandmetabolicparametersarandomizedcontrolledtrialsapporoatheroincretinstudy3 AT tsuchidakenichi effectsofvildagliptincomparedwithmetforminonvascularendothelialfunctionandmetabolicparametersarandomizedcontrolledtrialsapporoatheroincretinstudy3 AT mandanaoki effectsofvildagliptincomparedwithmetforminonvascularendothelialfunctionandmetabolicparametersarandomizedcontrolledtrialsapporoatheroincretinstudy3 AT kuriharayoshio effectsofvildagliptincomparedwithmetforminonvascularendothelialfunctionandmetabolicparametersarandomizedcontrolledtrialsapporoatheroincretinstudy3 AT aokishin effectsofvildagliptincomparedwithmetforminonvascularendothelialfunctionandmetabolicparametersarandomizedcontrolledtrialsapporoatheroincretinstudy3 AT nakamuraakinobu effectsofvildagliptincomparedwithmetforminonvascularendothelialfunctionandmetabolicparametersarandomizedcontrolledtrialsapporoatheroincretinstudy3 AT atsumitatsuya effectsofvildagliptincomparedwithmetforminonvascularendothelialfunctionandmetabolicparametersarandomizedcontrolledtrialsapporoatheroincretinstudy3 AT effectsofvildagliptincomparedwithmetforminonvascularendothelialfunctionandmetabolicparametersarandomizedcontrolledtrialsapporoatheroincretinstudy3 |